SM
ALDR

Sabby Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Sabby Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-46,800
Closed -$1.35M – 384
2015
Q1 		$1.35M Buy
+46,800
New +$1.28M 0.06% 169

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Sabby Management's ALDR Position: Q2 2015 in Review

Sabby Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2015, closing a stake of 46,800 shares — an estimated $1.35M sold.

Sabby Management first reported a position in ALDR in Q1 2015 and held it in 1 quarter. The position peaked at $1.35M in Q1 2015. 127 funds tracked by Wall St. Rank hold ALDR as of Q2 2015.

  • Sabby Management reported no remaining Alder Biopharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Sabby Management sold 46,800 Alder Biopharmaceuticals shares in Q2 2015, an estimated $1.35M.
  • Sabby Management first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Sabby Management's Alder Biopharmaceuticals position peaked at $1.35M in Q1 2015.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2015.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.